Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.

Keywords

Philosophy, Humanities, Political science, Economics

References

• The mosaic of autoimmunity.Yehuda Shoenfeld, David Isenberg — 1989
• α-Synuclein Shares Physical and Functional Homology with 14-3-3 ProteinsNatalie Ostrerova, Leonard Petrucelli, Matthew J. Farrer — 1999
• Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cellsAlessandra Handisurya, Sabine Gilch, Dorian Winter — 2007
• Autoantibodies to alpha-synuclein in inherited Parkinson’s diseaseKaterina K. Papachroni, Natalia Ninkina, Angeliki Papapanagiotou — 2006
• Therapeutic approaches for prion and Alzheimer's diseasesThomas Wısnıewskı, Einar M. Sigurdsson — 2007
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's diseaseRonald B. DeMattos, Kelly R. Bales, David J. Cummins — 2001
• Emerging pharmacotherapies for Creutzfeldt-Jakob disease.Carsten Korth, Peter J. Peters — 2006
• Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathiesSteffen Bade, Andreas Frey — 2007
• Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation.Roberto Hodara, Erin H. Norris, Benoit I. Giasson — 2004
• 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.Norman Relkin, Paul Szabo, Basia Adamiak — 2009
• Antibodies inhibit prion propagation and clear cell cultures of prion infectivityDavid Peretz, R. Anthony Williamson, Kiotoshi Kaneko — 2001
• Cytosolic Prion Protein (PrP) Is Not Toxic in N2a Cells and Primary Neurons Expressing Pathogenic PrP Mutations*Luana Fioriti, Sara Dossena, Leanne R. Stewart — 2005
• Has the amyloid cascade hypothesis for Alzheimer's disease been proved?John Hardy — 2006
• Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.Daniel Skovronsky, Virginia M.‐Y. Lee, John Q. Trojanowski — 2006
• Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein AntibodiesFrank L. Heppner, Christine Musahl, Isabelle Arrighi — 2001
• Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibodyMasato Enari, Eckhard Flechsig, Charles Weissmann — 2001
• S33.01 - Human anti-prion protein antibodies block A117V PrP peptide fibril formation and prevent A117V PrP peptide-induced neurotoxicityXinju Wei, Yantao He, Jian Tan — 2008
• Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer diseaseEliezer Masliah, Laura Hansen, Anthony Adame — 2005
• Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous SystemRobert D. Bell, Abhay P. Sagare, Alan E. Friedman — 2007
• Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.Marc E. Weksler, Norman Relkin, Rimma Turkenich — 2002

Cited by

• How our bodies fight amyloidosis: effects of physiological factors on pathogenic aggregation of amyloidogenic proteins.José Rodríguez Fernández — 2015
• Immunization as treatment for Parkinson's disease.Daniela Besong Agbo, Frauke Neff, Florian Seitz — 2009
• Identification of target antigens of naturally occurring autoantibodies in cerebrospinal fluid.Akio Kimura, Nobuaki Yoshikura, Akihiro Koumura — 2015
• Innovative Therapie der Alzheimer-DemenzRichard Dodel, Michael Bacher — 2008
• The Presence and Origin of Autoantibodies Against α4 and α7 Nicotinic Acetylcholine Receptors in the Human Blood: Possible Relevance to Alzheimer's PathologyLyudmyla Koval, Olena Lykhmus, Olena Kalashnyk — 2011
• Studies of α-synuclein Oligomers-with Relevance to Lewy Body DisordersTherese Fagerqvist — 2013
• Lowered Serum Amyloid-β1-42 Autoantibodies in Individuals with Lifetime DepressionWalter Maetzler, Markus Langkamp, Stefanie Lerche — 2012
• Epitope Fingerprinting for Recognition of the Polyclonal Serum Autoantibodies of Alzheimer's DiseaseLuiz Carlos de Oliveira-Júnior, Fabiana de Almeida Araújo Santos, Luíz Ricardo Goulart — 2015
• Alzheimers Disease: Review of Emerging Treatment Role for Intravenous ImmunoglobulinsRakez Kayed, George R. Jackson, D. Mark Estes — 2011
• Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.Bharath Wootla, Jens O. Watzlawik, Arthur E. Warrington — 2015
• Intravenous Immunoglobulins as a Treatment for Alzheimer’s DiseaseRichard Dodel, Frauke Neff, Carmen Noelker — 2010
• Involvement of the Fcγ Receptor in a Chronic N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss*Arman Lira, J Kulczycki, Ruth S. Slack — 2011
• An impedimetric assay of α-synuclein autoantibodies in early stage Parkinson's diseaseQiao Xu, Samuel Evetts, Michele Hu — 2014
• Naturally occurring auto-antibodies in homeostasis and disease.Hans Lutz, Christoph J. Binder, Srini V. Kaveri — 2009
• Is passive immunization for Alzheimer’s disease ‘alive and well’ or ‘dead and buried’?Gregory A. Jicha — 2009
• Thyroid Antibodies, Autoimmunity and Cognitive Decline: Is There a Population-Based Link?Kate Napthali, Michael Boyle, Huy Tran — 2014
• APP Transgenic Mice: Their Use and LimitationsClaudia Balducci, Gianluigi Forloni — 2011
• α-Synuclein: A therapeutic target for Parkinson’s disease?Kathleen A. Maguire‐Zeiss — 2008
• Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.F. Sardi, Lorenzo Fassina, Letizia Venturini — 2011
• Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and ControlsWalter Maetzler, Anja Apel, Markus Langkamp — 2014

Related papers

No related papers recorded.